Re-Vana Therapeutics Ltd.

Re-Vana Therapeutics Ltd. , based in the UK, specializes in innovative ocular delivery systems that utilize biodegradable implants for sustained therapeutic release, addressing significant needs in ocular medicine. Founded in 2015 and headquartered in Belfast, UK, Re-Vana Therapeutics Ltd. focuses on developing advanced ocular drug delivery solutions.

The founders, David Jones and Raghu Thakur, established the company to improve the management of sight-threatening diseases. In November 2022, the company raised USD 5. 48 mn in Series A funding, led by Visionary Venture Fund, to further advance its proprietary technologies. To date, Re-Vana has completed four deals, with the latest deal occurring in November 2022, bringing its total funds raised to USD 5.

48 mn and a current company valuation of USD 18. 28 mn. Re-Vana Therapeutics specializes in innovative ocular delivery systems, focusing on biodegradable implants designed for sustained release of therapeutics. Their core products, EyeLief® and OcuLief®, utilize patented technology to facilitate the controlled intraocular release of Active Pharmaceutical Ingredients (APIs) over extended periods, addressing the needs of patients suffering from sight-threatening diseases.

EyeLief® is a pre-formed, photo-crosslinked biodegradable implant that provides sustained release for up to six months at adjustable rates, making it suitable for small, potent molecules. OcuLief®, on the other hand, is an injectable gel that forms a crosslinked implant in situ, allowing for higher release rates of biologics over six to twelve months. Re-Vana’s products are positioned within the global ophthalmic pharmaceutical market, targeting healthcare providers and pharmaceutical companies across North America, Europe, and Asia, ultimately serving patients who require long-acting ocular therapies. The revenue model for Re-Vana Therapeutics is primarily driven by strategic partnerships with leading pharmaceutical companies, focusing on the development and commercialization of their innovative ocular delivery technologies.

The company engages in B2B transactions, collaborating with pharmaceutical partners to conduct preformulation and preclinical feasibility studies that lead to the integration of Re-Vana’s technologies into existing treatment frameworks. Revenue generation may stem from licensing agreements where pharmaceutical firms pay to utilize Re-Vana's patented technologies, potentially structured as upfront fees followed by milestone payments tied to regulatory progress and commercial success. The flagship products, EyeLief® and OcuLief®, represent significant avenues for revenue, as these advanced implantable systems are designed to meet the increasing demand for sustained-release formulations in the ophthalmic market. In November 2022, Re-Vana Therapeutics Ltd.

raised USD 5. 48 mn in Series A funding, led by Visionary Venture Fund, to support the advancement of its novel and proprietary photo-crosslinked EyeLief, EyeLief-SD, and OcuLief biodegradable drug delivery technologies. The company plans to utilize this funding to accelerate product development and expand its team. Re-Vana aims to introduce new products into the market and expand its geographic footprint, targeting additional regions in Europe and Asia by 2024.